Infantile Spasms Therapeutics Market

An infantile spasm (IS), also known as West Syndrome, is a specific type of seizure seen in an epilepsy syndrome of infancy and childhood. West Syndrome is characterized by infantile spasms, developmental regression, and a specific pattern on electroencephalography (EEG) testing called hypsarrhythmia (chaotic brain waves). The onset of infantile spasms is usually in the first year of life, typically between 4-8 months. The seizures primarily consist of a sudden bending forward of the body with stiffening of the arms and legs; some children arch their backs as they extend their arms and legs. The condition is usually observed in 2% of childhood epilepsies and 25% of epilepsies that start in the first year of life.

Infantile Spasms Therapeutics Market contains market size and forecasts of Infantile Spasms Therapeutics in Global, including the following market information:

Global Infantile Spasms Therapeutics Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Infantile Spasms Therapeutics market was valued at 146.1 million in 2021 and is projected to reach US$ 185.2 million by 2028, at a CAGR of 3.4% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Oral Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Infantile Spasms Therapeutics include Mallinckrodt, H. Lundbeck, Insys Therapeutics, Orphelia Pharma, Valerion Therapeutics, Catalyst Pharmaceuticals, Anavex Life Sciences, Retrophin and GW Pharmaceuticals. etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Infantile Spasms Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Infantile Spasms Therapeutics Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Infantile Spasms Therapeutics Market Segment Percentages, by Type, 2021 (%)

Oral

Injection

Global Infantile Spasms Therapeutics Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Infantile Spasms Therapeutics Market Segment Percentages, by Application, 2021 (%)

Hospital

Clinic

Other

Global Infantile Spasms Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Infantile Spasms Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Infantile Spasms Therapeutics revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Infantile Spasms Therapeutics revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Mallinckrodt

H. Lundbeck

Insys Therapeutics

Orphelia Pharma

Valerion Therapeutics

Catalyst Pharmaceuticals

Anavex Life Sciences

Retrophin

GW Pharmaceuticals